As a dedicated life science venture firm, Red Tree employs a West Coast-centric, early stage-biased investment strategy. We focus primarily on entrepreneurs developing first-in-class and/or best-in-class therapeutics addressing significant unmet needs in the areas of oncology, neurology, and immunology.